Corteva (CTVA), a prominent name in the bio-tech market, has seen varied activities. It has been observed that shares of Corteva have been sold by both Tocqueville Asset Management L.P. and Mitsubishi UFJ Trust & Banking Corp. Simultaneously, Kingsview Wealth Management LLC has increased its position in the company. There is a mixed opinion about whether one should hold Corteva (CTVA) for the long term. Interestingly, the company has risen amidst a robust outlook for farmer spending on crops. The value holding of CTVA by various asset management firms such as BNP Paribas and Swiss National Bank has fluctuated. Still, Corteva has outperformed the market despite its losses. Additionally, the company's recent quarterly earnings report expects a promising return trend despite recent stock falls. Furthermore, the sale of resistant starch durum wheat trait to Corteva has been announced by Arcadia Biosciences (RKDA), which may potentially influence CTVA's fortunes. As of Q4, Corteva has delivered upbeat profits with plans for a $1 billion share buyback. The company's five-year journey marked value creation despite facing market challenges.
Corteva CTVA News Analytics from Mon, 09 Oct 2023 07:00:00 GMT to Sun, 21 Jul 2024 18:18:38 GMT -
Rating 6
- Innovation 7
- Information 8
- Rumor 0
